# Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

> **NCT05246384** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Rhizen Pharmaceuticals SA**

## Conditions studied

- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** RP7214

## Key facts

- **NCT ID:** NCT05246384
- **Lead sponsor:** Rhizen Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-01
- **Primary completion:** 2024-12
- **Final completion:** 2025-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change in development plan
- **Last updated:** 2022-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05246384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05246384, "Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05246384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*